导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.41% | 2958/4773 |
| 近一周 | -2.22% | 4178/5467 |
| 近一月 | 1.19% | 250/5421 |
| 近一季 | 3.10% | 523/5238 |
| 近半年 | -2.31% | 2281/4931 |
| 近一年 | 2.03% | 2141/4400 |
| 近两年 | 27.90% | 2351/2954 |
| 近三年 | 24.18% | 1318/2253 |
| 成立以来 | 43.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.63% 3317/4961 |
-5.28% 3555/5312 |
- - |
- - |
| 2025 | 8.83% 2891/4813 |
-1.97% 2826/3635 |
5.39% 601/4076 |
-0.90% 3943/4524 |
6.29% 365/4813 |
| 2024 | 27.09% 202/3463 |
8.56% 180/2808 |
3.57% 265/3014 |
13.98% 2065/3129 |
-0.83% 1529/3463 |
| 2023 | -1.26% 498/2656 |
3.49% 1182/2280 |
0.95% 259/2385 |
2.21% 247/2515 |
-7.52% 2163/2655 |
| 2022 | -10.18% 200/2207 |
-4.61% 169/1919 |
-0.53% 1633/2016 |
-8.33% 192/2113 |
3.28% 732/2208 |
| 2021 | 2.03% 641/1822 |
6.12% 99/1255 |
-3.11% 1237/1330 |
-1.15% 508/1466 |
0.37% 1125/1822 |
| 2020 | 6.95% 871/1250 |
-13.03% 917/1028 |
3.24% 945/1067 |
10.05% 594/1164 |
8.24% 684/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.47% 714/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 申万菱信沪深300价值指数C VS. 长安沪深300非周期A(740101) |